We are international
Donate
• about myeloma TEXT SIZE   
Ask Dr Durie

ask_dr_durie_banner



Have a question? Submit it to AskDrDurie@myeloma.org!

facebook
googleplus
twitter
youtube


If you have a question to ask Dr. Durie please email us at AskDrDurie@myeloma.org. We review all questions and will do our best to have your question answered by Dr. Durie.  You can also submit your question via one of the social media channels listed above.

 

The IMF has a vast library of information that is of interest to patients, caregivers, healthcare professionals and other interested parties.  

Click here to visit out library.





#Ask Dr. Durie
    next      view all

09.25.14   #AskDrDurie: What is Selinexor

In this week's episode of #AskDrDurie, Dr. Brian Durie of the IMF takes a question from a patient who has relapsing myeloma and is wondering about the new drug Selinexor. Dr. Durie explains what the drug is and how it can be used in myeloma.


09.18.14   #AskDrDurie: Is autologous stem cell transplant still recommended?

In this episode of the IMF’s #AskDrDurie web series, Dr. Brian Durie talks about when and for what kind of myeloma patient an autologous stem cell transplant (ASCT) is recommended.


09.10.14   #AskDrDurie: Has there been any change in recommendations used to treat bone disease in myeloma?

In this week's episode of #AskDrDurie, the IMF's Chairman Dr. Brian Durie answers a patient's question regarding how bone disease in myeloma is treated. He discusses bisphosphonates such as Aredia and Zometa and what the current recommendations are.


09.03.14   #AskDrDurie: If Pomalyst does not produce a full response, what are my options?

In this episode of #AskDrDurie, Dr. Brian Durie explores options for myeloma treatment if a patient isn’t receiving a full response from Pomalyst.


08.27.14   #AskDrDurie: Is there a test available for measuring Minimal Residual Disease, what we call MRD?

In this week's #AskDrDurie, the IMF's Dr. Brian Durie answers a very important question regarding the tests available for measuring Minimal Residual Disease. As you may know, the IMF's Black Swan Research Initiative(R) has been evaluating a new flow test method for this, and it is becoming a new benchmark.


08.13.14   #AskDrDurie: How can Revlimid’s diarrhea side effect be handled?

In this episode of #AskDrDurie, the IMF's Dr. Brian Durie answers a patient's question about dealing with a specific side effect from Revlimid.


08.07.14   #AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


07.30.14   #AskDrDurie: What are the important aspects of different types of imaging, such as regular x-rays, MRI, CT, and PET?
In this week's #AskDrDurie episode, Dr. Brian Durie of the IMF explains the difference between x-rays, MRI, CT, and PET image scans. Each one has its place in detecting myeloma, and he walks viewers through each.

07.23.14   #AskDrDurie: Should I have an ASCT if I've been through therapy and am in remission?

In this week's #AskDrDurie, IMF Chairman and Co-Founder, Dr. Brian Durie answers a patient's inquiry about the benefits and necessity of having an autologous stem cell transplant (ASCT) if treatment for myeloma has already been completed, with remission as the result.


07.16.14   #AskDrDurie: How can myeloma suddenly go from standard to high risk?
In this episode of #AskDrDurie, IMF Co-Founder and Chairman Dr. Brian G.M. Durie answers a patient submitted question regarding receiving an initial diagnosis of standard myeloma, having treatment, and then being told the myeloma was high risk. He explains when and why that can happen and discusses different kinds of testing involved.

    next      view all